Why kidney transplants fail ca. 2012
#RKDSummit #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/22081892/
1
0
0
0
Hashtag
#RKDSummit
Advertisement · 728 × 90
Trying to catch up with #IgAN trials⁉️
Check out “IgAN: An Overview of the Clinical Trials” ca. 2025 from @kidneymed.bsky.social
#Nephpearls #RKDSummit #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41050133/
5
1
0
0
Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy (IgAN) in Adults
#RKDSummit #Nephpearls #NephSky
👉🏼 www.otsuka.co.jp/en/company/n...
1
0
0
0
APRIL is key 🔑 in the development of Antibody-secreting B lymphocytes ca. 2018 from @JASN_News
#IgAN #Nephpearls #RKDSummit #NephSky
👉 pubmed.ncbi.nlm.nih.gov/29326157/
7
1
1
0
Pathogenesis of #IgAN and emerging targets 🎯 ca. 2025
#RKDSummit #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/40796290/
3
1
0
0
Impact of Using Risk-Based Stratification on Referral of Patients With CKD From Primary Care to Specialist Care in the United Kingdom ca. 2021 from @kireports.bsky.social
#RKDSummit #Nephpearls #NephSky
#VisualAbstract by @hellokidneymd.bsky.social
👉🏼 pubmed.ncbi.nlm.nih.gov/34386668/
2
1
0
0
Treatment targets 🎯 in IgA Nephropathy #IgAN and the positioning of drugs ca. 2025 from @kdigo.org
#Nephpearls #RKDSummit #NephSky
📌 Proteinuria >/= 0.5 g/day (or equivalent) ~ at risk of progressive loss of kidney function
👉🏼 kdigo.org/guidelines/i...
4
3
0
0
A stylized representation of the unmet need in a typical adult patient with #IgAN
#RKDSummit #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/39211339/
1
0
0
0
DAPA-CKD: SGLT2 inhibitors (SGLT2i) in IgA Nephropathy and FSGS
#RKDSummit #Nephpearls #NephSky
🔬 IgA Nephropathy
pubmed.ncbi.nlm.nih.gov/33878338/
🔬 FSGS
pubmed.ncbi.nlm.nih.gov/34850160/
1
0
0
0
Actionable genes in CKD ca. 2024 from @kdigo.org
#RKDSummit #Nephpearls #NephSky
👉 kdigo.org/guidelines/c...
4
4
0
0
Genetics 🧬 of FSGS
#VisualAbstract sightings from @kidneyboy.bsky.social @rheaultm.bsky.social @asnpublications.bsky.social
#RKDSummit #Nephpearls
👉🏼 pubmed.ncbi.nlm.nih.gov/30647093/
👉🏼 pubmed.ncbi.nlm.nih.gov/35474271/
👉🏼 pubmed.ncbi.nlm.nih.gov/39190490/
2
1
0
0
Spectrum of podocytopathies: Interaction between genetics 🧬 and environment
#RKDSummit #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/17410103/
3
1
0
0
Clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome (NS) ca. 2023
#RKDSummit #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/36269406/
1
0
0
0
Potential of antinephrin autoantibody measurement for a noninvasive diagnosis of antinephrin-associated podocytopathy ca. 2025 from @kireports.bsky.social
#RKDSummit #Nephpearls
#VisualAbstract by @brianrifkin.bsky.social
👉🏼 pubmed.ncbi.nlm.nih.gov/40814620/
3
2
0
0
Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria ca. 2025 from @asnpublications.bsky.social
#RKDSummit #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/40244693/
0
0
0
0
Which patients should be on SGLT2 inhibitors (SGLT2i) ⁉️
✅ Check out the SGLT2i Cold 🥶 Map from @theisn.org
#RKDSummit #Nephpearls #NephSky
👉🏼 www.theisn.org/initiatives/...
4
1
0
0
Interrelation of mechanistic drivers in early through advanced stages of kidney damage and disease progression in diabetes ca. 2022
#RKDSummit #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/35661785/
1
0
0
0
High unmet treatment needs in patients w/ CKD & type 2 diabetes (T2D): RWE from a US claims database ca. 2023
#RKDSummit #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/35389468/
📌 Low initiation rates of SOC (ACEi/ ARB) overall & SGLT2i
📌 There were high discontinuation rates for all treatments
0
0
0
0
Theoretical framework for the implementation of GDMT in Type 2 Diabetes (T2D) and CKD ca. 2024
#RKDSummit #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/38620082/
1
0
0
0
Barriers to appropriate medication prescribing and use in CKD ca. 2024
#RKDSummit #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/39815796/
2
1
0
0
Stages of cardiovascular-kidney-metabolic (CKM) syndrome
#RKDSummit #Nephpearls #Cardiorenal #NephSky
👉 pubmed.ncbi.nlm.nih.gov/37807924/
2
1
0
0
Kidney Failure Events, Cardiovascular Disease Events, and All-Cause Mortality in Patients with IgA Nephropathy #IgAN in a Real-World Database ca. 2024 from @asnpublications.bsky.social
#RKDSummit #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/38323871/
2
0
0
0
Podocyte loss correlation with disease progression
#RKDSummit
0
0
0
0
Next up Matthias Kretzler on targeted therapies of FSGS
This makes a lot of sense and starts to operationalize the concept that FSGS is a pattern of injury rather than a disease.
#RKDSummit
0
0
0
0
When to do genetic testing in FSGS
#RKDSummit
0
0
1
0
0
0
1
0
0
0
1
0
0
0
1
0
Columbia classifications
A consensus classification
Not based on quantifiable data. No outcome data.
But subsequent work showed that collapsing is the worst and tip is the best.
#RKDSummit
0
0
1
0
Next up is Charles Alpers to discuss the pathologists approach.
FSGS is a pattern(s) of injury observed on light
Not dependent on IF
Not dependent on EM
Lacks an active inflammatory component
#RKDSummit
0
0
1
0